Search
4 days ago
SITC 2024: Parker Institute for Cancer Immunotherapy CSO John Connolly gives an overview of the latest advances in IO
He discusses the latest in TILs, cell therapy, multispecifics, oncolytic viruses and more.
Nov 4, 2023
Parker Institute for Cancer Immunotherapy's John Connolly on what he is seeing at #SITC23
John Connolly describes trends he is seeing in cell therapy, bi-specific engagers, myeloid checkpoint targets, and combinations.
Jan 11, 2023
The latest on immunotherapy with John Connolly.
Parker Institute's John Connolly provides an update on the latest in cancer immunotherapy at #JPM23.